Statement on accelerated approval of Leqembi to treat mild-stage Alzheimer’s disease in the general population
On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for lecanemab, an anti-amyloid drug to treat Alzheimer’s disease that was developed by Eisai and Biogen. […]
Impact Report 2022
Our Impact Report 2022 highlights our accomplishments as an organization during a remarkable year. 2022 saw Down syndrome research receive unprecedented attention from policymakers, the media, and the pharmaceutical and […]
New steps forward in treating Alzheimer’s disease with lecanemab: Clinical trial reveals clear efficacy in removing brain plaque
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for an antibody drug candidate called lecanemab. (Read more about the development of lecanemab here.) An […]
DS-CTN Data and Safety Monitoring Board (DSMB)
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch of the DS-CTN Data and Safety Monitoring Board (DSMB). This service was created to provide […]
Lecanemab: New Treatment for Alzheimer’s Disease
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced positive “topline” results from the clinical trial of their anti-amyloid antibody, lecanemab, in patients with […]
NTG Publishes Advisory on Long-COVID in Adults with Intellectual Disability
In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices (NTG) published an article providing background information on the residual and potentially long-term effects of Long-COVID, […]
Why is Down syndrome research important?
[fancy_box box_style=”parallax_hover” icon_family=”none” image_url=”7558″ link_new_tab=”true” parallax_hover_box_alignment=”middle” parallax_hover_box_overlay=”#f69220″ parallax_hover_box_overlay_opacity=”0.2″ parallax_hover_box_overlay_opacity_hover=”0.6″ border_radius=”default” image_loading=”default” image_size=”square” link_url=”https://dsctn.org/interested-in-participating-in-ds-research/”] Learn more about Down syndrome research [/fancy_box][fancy_box box_style=”parallax_hover” icon_family=”none” image_url=”5520″ parallax_hover_box_alignment=”middle” parallax_hover_box_overlay=”#001e61″ parallax_hover_box_overlay_opacity=”0.2″ parallax_hover_box_overlay_opacity_hover=”0.6″ border_radius=”default” image_loading=”default” image_size=”square” […]
Potential New Therapy for Adults with Down Syndrome
September 16, 2022 Research recently published in the journal Science (Manfredi-Lozano et al., Science 377, eabq4515 (2022)) raises the possibility that a currently approved drug may offer an effective boost […]
LIFE-DSR: up close and personal with John
In July 2022, John Cronin and his parents invited LuMind IDSC to follow their family experience as they participated in their LIFE-DSR study visit. This one-of-a-kind peek into research was […]
A Closer Look at the CMS Decision on Aduhelm and Anti-Amyloid Drugs
AN EXPLAINER FOR THE DOWN SYNDROME COMMUNITY April 15, 2022 BACKGROUND On April 7, 2022, the federal Centers for Medicare and Medicaid (CMS) finalized their coverage policy for drugs known as […]